Clinical trials: Breast Cancer Nos Metastatic Recurrent
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00577122
- Testing
- Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.
- Trial name
- NCT00003761
- Testing
- rV-DF3/MUC1
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT01105312
- Testing
- letrozole, panobinostat, RNA analysis
- Where
- 172 sites in United States
- Volunteers
- 28 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
This is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy.
- Trial name
- CAPItrue (NCT06635447)
- Testing
- Capivasertib, Fulvestrant
- Where
- 76 sites in China
- Volunteers
- 293 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Breast Tumors
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Tumors, Breast Cancer, Locally Recurrent and Metastatic Breast Cancer
- Trial name
- NCT00356681
- Testing
- Bevacizumab, AMG 706, Paclitaxel
- Volunteers
- 282 people
- Sponsor
- Amgen
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04529044
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with…
- Trial name
- NCT07111832
- Testing
- SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Breast Cancer
Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of liposomal doxorubicin is more effective for metastatic breast cancer.
- Trial name
- NCT00005980
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 14 sites in Austria, France and 7 more
- Volunteers
- 116 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumors, Advanced Triple Negative Breast Cancer
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
This is a Phase 1b/2a dose escalation and expansion, multi-center study to be conducted in 2 phases: Phase 1b Dose Escalation Part 1 (Doublet Therapy) Dose Escalation Part 2 (Triplet Therapy) Phase 2a Dose Expansion (Triplet…
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer
- Trial name
- NCT03861403
- Testing
- TRX518, Cyclophosphamide, Avelumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Breast Cancer
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without…
- Trial name
- NCT00006381
- Testing
- trastuzumab, celecoxib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Metastatic Cancer
Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases.
- Conditions
- Breast Cancer, Metastatic Cancer, Pain, Prostate Cancer
- Trial name
- NCT00003162
- Testing
- pain therapy, radiation therapy
- Where
- 253 sites in United States, Canada
- Volunteers
- 949 people
- Sponsor
- Radiation Therapy Oncology Group
Triple Negative Breast Cancer, Surveillance
Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms…
- Conditions
- Triple Negative Breast Cancer, Surveillance, Recurrence, ctDNA
- Trial name
- EINSTEIN-TNBC (NCT07478705)
- Testing
- ctDNA-guided imaging surveillance, Standard
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Metastatic Cancer
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00450866
- Testing
- epothilone B
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- David Peereboom, MD
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating older women who have stage IV…
- Trial name
- NCT00022152
- Testing
- vinorelbine tartrate
- Where
- 18 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology